Revati Tatake, Global head of Pharma and Competitive Intelligence, GlobalData, speaks about the latest clinical trial, drug development and licensing trends from China at the Outsourcing in Clinical ...
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of orforglipron and oral semaglutide in adults with type 2 diabetes ...
Ahead of Rare Disease Day, Abigail Beaney, editor of Clinical Trials Arena, spoke with Robert Barrie, editor of Pharmaceutical Technology and Frankie Fattorini, reporter for Pharmaceutical Technology ...
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...
An estimated 300 million people globally are living with rare conditions. Credit: jittawit21 / Shutterstock.com As we mark Rare Disease Day 2026, it is worth reflecting on the developments in ...
The double-blind, placebo controlled trial enrolled 71 patients with SAD. Credit: Elena Kalinicheva / Shutterstock.com AtaiBeckley’s social anxiety disorder (SAD) drug has shown both safety and early ...
The global, randomised SYNERGY-101 trial began enrolling patients in November 2025, with the first patient already dosed. Credit: Motortion Films / Shutterstock.com. Synthekine has entered a clinical ...
ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE trial (NCT05996471), lotivibart, a broadly neutralising antibody, ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
Jaguar Gene Therapy has completed Cohort I dosing of its first-in-human clinical trial investigating JAG201 for patients with SHANK3 haploinsufficiency.
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results